BeyondSpring : Market Opportunities & Strategies

Optimizing success in cancer treatment

March 2020 | NASDAQ: BYSI

beyondspringpharma.com

1. B A Y

S	S	Assessing the Plinabulin opportunity
D	I
A
Q

THE CURRENT CHEMOTHERAPY	THE UNMET NEED IN	THE POTENTIAL	HCP AND PAYER	GO-TO-MARKET
LANDSCAPE	CHEMOTHERAPY-INDUCED	OF PLINABULIN	RESPONSE TO PLINABULIN	PLANS
	NEUTROPENIA (CIN)		PRODUCT PROFILE

2

1. B A Y S S D I A
   Q

beyondspringpharma.com

The chemotherapy market gap

Healthcare professionals (HCPs) consider preventing CIN very important

to ensure patients receive the maximum benefit of chemotherapy1

MONOTHERAPY GRANULOCYTE-COLONY

STIMULATING FACTOR (G-CSF) DOESN'T ALLOW

FOR CHEMOTHERAPY OPTIMIZATION3

20182

CIN	BONE PAIN
remains the #1 reason for	remains significant
chemotherapy disruption2	clinical issue3

2040

SLIGHT CHANGES IN DOSING OR DELIVERY CAN HAVE A DEVASTATING IMPACT ON SURVIVAL4

1A

MONOTHERAPY G-CSF IS SUBOPTIOMAL AND LEAVES A SIGNIFICANT CLINICAL GAP

PLINABULIN + G-CSF HAS POTENTIAL TO ADDRESS THIS IMPORTANT UNMET CLINICAL NEED

1. Proprietary market research, BYSI Summer/Fall 2019. 2. LaLami. 3. Moore. 4. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.	3
N Engl J Med 1995;332:901-906

CURRENT

CHEMOTHERAPY LANDSCAPE

1. B A Y S S D I A
   Q

beyondspringpharma.com

Significant opportunities exist to improve the standard of care

for patients on chemotherapy

Chemotherapy remains

THE CORNERSTONE OF TREATMENT

for most cancers

~650,000

U.S. PATIENTS

receive chemotherapy annually1

~1.3 MILLION CYCLES

of G-CSF used annually in the US

MYELOSUPPRESSION is currently an

unavoidable consequence of chemo that impacts patient safety and quality of life

Neutropenia and anemia

Chemotherapy dose delays and reductions

Risk of infection: G-CSF use, associated bone pain

Impaired anti-tumor immunity

Hospitalizations and unscheduled office visits

Red blood cell transfusions and erythropoiesis- stimulating agent rescue

Fatigue

Risk of bleeding: platelet transfusion

5

1. Centers for Disease Control and Prevention. Information for Health Care Providers. Available at: www.cdc.gov/cancer/preventinfections/providers.htm. Accessed February 21, 2020.

beyondspringpharma.com

1. B A Y

S	S	50%+ growth expected in use of first-line chemotherapy by 2040
Q	I
D
A

▪ The global chemotherapy market will continue to experience aggressive growth

- Globally new cases of cancer are expected to increase from 17M in 2018 to 26M in 2040

- First-line chemo patient growth: 53%

▪ More aggressive approaches, (e.g. Immuno-oncology + chemo will require improved CIN support)

▪ Plinabulin + G-CSF data demonstrate potential to support more aggressive chemotherapy with the potential for improved patient outcomes

Brooke E Wilson, Susannah Jacob, Mei Ling Yap, Jacques Ferlay, Freddie Bray, Michael B Barton; Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-	6
based study; www.thelancet.com/oncology Published online May 8, 2019 http://dx.doi.org/10.1016/S1470-2045(19)30163-9 1

1. B A Y S S D I A
   Q

beyondspringpharma.com

Treating CIN is an important priority for HCPs

HOW MUCH OF A PRIORITY IS TREATING CIN

IN RELATION TO OTHER COMPLICATIONS OF CHEMOTHERAPY?

Extreme Moderate Not at all

1%

23%

76%

7

QA08: In a patient's overall treatment plan, how much of a priority is treating CIN relative to other complications of chemotherapy (e.g. liver/renal toxicity, nausea/vomiting, anemia, etc.)?

beyondspringpharma.com

1. B

A	Y	$7+ billion opportunity in CIN global market
A	S
S
D	I
Q
		Plinabulin can potentially be used with each cycle of G-CSF in chemotherapy to provide
		improved protection from neutropenia

$5+B/yr:

THE US IS THE LARGEST MARKET FOR CIN

Plinabulin + G-CSF Addressable Market:

• US: 1.3M G-CSF cycles/year
• Global: 4M G-CSF cycles/year

CANADA

EU 5

AUSTRALIACHINA

SOUTH KOREA

JAPAN

8

Note: 1 https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21338. G-CSF market growth based on IQVIA data (MIDAS for ex-U.S. and DDM MD for U.S.; Q3 '16 to Q2 '18. Standardized G-CSF units

beyondspringpharma.com

1. B

A	Y	G-CSF Biosimilars: Plinabulin commercial accelerators
A	S
S
D	I
Q

Combination therapy required to address unmet medical need

Biosimilar success coming at Amgen's expense

Aligns with Plinabulin's combination strategy

Market Share YE '191

• Increased choice
• Decrease price
• • Biosimilar list price ~33% below branded
  • Average selling price (ASP) continues to decline for all products
  • The gap shows no sign of slowing

Current difference between branded and biosimilar ASP between $2,400 and $2,800/cycle

All trends favor Plinabulin's combination strategy

Neulasta Family (Amgen)	Fulphila (Mylan)
Udenyca (Coherus)	Other

1 shares approximate; not all G-CSF companies report market share performance 9

by product. Based on company filings and investor conference presentations

THE UNMET NEED

CHEMOTHERAPY WITHOUT COMPROMISE

1. B A Y S S D I A
   Q

beyondspringpharma.com

Unmet need not addressed by monotherapy G-CSF

Efficacy and safety of chemotherapy compromised by substandard care

Neulasta® after TAC for breast cancer

		Efficacy	Neulasta 6.0 mg1	Neulasta 6.0 mg2
		n=29	n=61
Efficacy issue
					Neutropenia:
Neutropenia (grade 3/4)	96.6%	100%
			•	Grade 3 >0.5 & <1.0
		Mean ANC nadir (109/L)	0.255 ± 0.287	0.266
			•	Grade 4 >0.5

Neulasta after chemotherapy

		Safety	Neulasta 6.0 mg3	Neulasta 6.0 mg4
		n=100
Safety issue
Bone pain (score of 1-10)	59%	71%
		Severe bone pain (score of 6-10)	24%	27%

Note: 1 Masuda N et al., Support Care Cancer 23: 2891-2898 (2015). 2 Lee J et al., Annals of Surgical Treatment and Research 94(5): 223-238 (2018). 3 Kirshner et al.,

Comm Onc 4:455-459 (2007). 4 Xu et al., Support Care Cancer 24:723-730 (2016). 5 Lalami et al., Critical Reviews in Oncology / Hematology 120 163-179 (2017). ). 6

O'Regan et al., Clinical Breast Cancer 6(2): 163-168 (2005). 7 Vasey et al., British J Cancer 87: 1072-78 (2002). 8 Alba et al. JCO 22(13): 2587-93 (2002).

Neulasta® is a registered trademark of Amgen, Inc.

11

beyondspringpharma.com

1. B

A	Y	Monotherapy G-CSF is not enough
A	S
S
D	I
Q

Despite a broad use of monotherapy G-CSFs, the "4Ds" are a vexing clinical challenge for preventing neutropenia

DECREASED	DELAYED	DOWNGRADE	DISCONTINUED
recommended dose	cycles	chemotherapy regimen	chemotherapy

…CIN and/or febrile neutropenia may have long-term effects with clinical impact on the overall chemotherapy treatment plan, resulting in dose reductions and/or treatment delays, chemotherapy discontinuation, or a switch to less toxic alternatives, and potentially less effective regimens, leading finally to decreased response and survival rates.1

12

1. Segal et al., 2008; Schwenglenks et al., 2006.

beyondspringpharma.com

1. B

A	Y	Maintaining dose and dosing schedules are critical for survival
A	S
S
D	I
Q

	DOSE REDUCTIONS = DECREASED OVERALL SURVIVAL1		DELAYED CYCLES = DECREASED
								OVERALL SURVIVAL2
BREAST CANCER		OVARIAN CANCER
		Dose reduction ≥15% (n=408)	Median years (95% Cl)			Dose reduction ≥15% (n=82)	Median years (95% Cl)
		2.31 (1.87-2.87)			2.30 (1.67-4.12)
		Dose reduction <15% (n=411)			Dose reduction <15% (n=88)
		3.67 (3.15-4.19)			3.24 (3.00-NR)
		Log-rankP value			Log-rankP value
		0.0195			0.0114

.

13

1 . 2. Chirivella I et al. Breast Cancer Res Treat. 2009;114:479-484

1. B A Y S S D I A
   Q

beyondspringpharma.com

Universal challenge of maintaining therapy

Dose reductions, delays, and missing doses by therapy (even with use of G-CSF)

16,000 patients

Despite broad-base use of monotherapy G-CSF, HCPs still struggle to deliver

▪ On time doses

▪ Full dose chemotherapy

▪ Full course chemotherapy

RESULT:

Chemotherapy is sub-optimized

HCPs recognize the clinical gap

STANDARD REGIMEN COHORT

14

Published, 2015. Per EMR review of 16,233 patients with 6 different tumor types 2007-2011.JNCCN-Journal of the National Comprehensive Cancer Network Volume 13 Number 11 November 2015.

1. B A Y S S D I A
   Q

beyondspringpharma.com

Compromised therapy: Quantifying the unmet market need

Shrink the Red

Breast; n = 10,435

Dose Reduction2

33%

67%

>= 15% < 15%

Dose Delay2

38%

62%

NSCLC; n = 609

Dose Reduction2

32%

68%

>= 15% < 15%

Dose Delay2

34%

66%

NHL; n = 1,852

Dose Reduction2

44%

56%

>= 15% < 15%

Dose Delay2

36%

64%

IMS PharmMetrics Plus™ study:

• 23% of Neulasta cycles were administered on days
  other than the day after chemotherapy3
• The study included over 200,000 Neulasta cycles from 2 patient databases. Approximately 14,000
  cycles included Neulasta Onpro®3

>= 7 Days	< 7 Days	>= 7 Days	< 7 Days	>= 7 Days	< 7 Days
Note: 1Denduluri N, Patti DA, Wang Y, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr
Netw. 2015;13(11):1383-1394.2 Based on planned regimen(95% CI). 3Retrospective cohort analysis based on health care claims from IMS PharMetrics Plus™ and Truven Health Analytics MarketScan® Commercial and Medicare
Supplemental Databases. The collective data include health care claims from private US health plans, covering over 30 million persons annually. The data included all patients ≥ 18 years who, between July 1, 2010, and September
30, 2015, initiated ≥ 1 course of myelosuppressive chemotherapy for a primary solid tumor or non-Hodgkin's lymphoma. All patients who received a selected chemotherapy regimen with a risk of FN and pegfilgrastim prophylaxis in
≥ 1 cycles of chemotherapy were selected for inclusion in the study population. FN requiring inpatient care was identified based on an inpatient admission with a diagnosis (principal or secondary) of neutropenia, fever, or	15
infection using ICD-9 and ICD-10 codes. FN requiring outpatient care was only ascertained based on an encounter in the outpatient setting with a diagnosis of neutropenia, fever, or infection, and-on the same date-code for IV
administration of antimicrobial therapy.

beyondspringpharma.com

1. B

A	Y	Monotherapy G-CSF unmet medical need - Summary
A	S
S
D	I
Q

Severe neutropenia still at 96 - 100% even with the use of G-CSF for high risk chemo

Severe neutropenia causes RDI reductions

• RDI reductions = reduced survival

Bone pain is a significant challenge for patients

Monotherapy G-CSF does not have the potential to provide anti-cancer benefits

15% 50%

Reduction in Relative	Reduction in Overall
Dose Intensity	Survival

Clinical evidence indicates that dose reduction is

associated with decreased survival.

A more aggressive approach to CIN is needed.

Combination therapy with Plinabulin can address the

unmet clinical need.

16

PLINABULIN

THE POTENTIAL TO ELEVATE THE STANDARD OF CARE

beyondspringpharma.com

1. B

A	Y	Plinabulin sets a new standard of care
A	S
S
D	I
Q
		Plinabulin + G-CSF has the potential to enhance chemotherapy care in the prevention of neutropenia
		Additionally, Plinabulin has demonstrated direct anti-cancer benefits in pre-clinical & clinical trials

REDUCTION OF

SEVERE NEUTROPENIA

Combination prevents Grade 3/4

Neutropenia

82.00%

39% ↓

p = 0.03

50.00%

Peg 6 mg (n=21) Plin 20 mg + Peg 6 mg (n=16)

INCREASED RDI/

POTENTIAL FOR OS

Combination improves RDI: Percent of Patients >85% RDI

93.75%

80.95%

Peg 6 mg

Plin 20 mg + Peg 6 mg

REDUCES BONE

PAIN

Combination reduces bone pain

	100%	95%	p < 0.0001
	90%
	80%
	70%
of patients	60%
50%
40%				36%		p < 0.01
%
	30%
	20%
	10%	6%		0%
	0%
		1	2	3	4	5	6	7	8

At least X days of bone pain

Neulasta 6mg (n=22)

Plinabulin 20mg + Neulasta 6mg (n=16) 18

1. B A Y S S D I A
   Q

beyondspringpharma.com

Plinabulin has the power to transform the treatment journey

Chemotherapy Without Compromise

WITH LESS	WITH LESS	WITH HIGHER NADIR AND SHORTER	WITH NO
GRADE 3 AND 4 CIN	BONE PAIN	DEJERINE-SOTTAS NEUROPATHY	THROMBOCYTOPENIA

		TODAY		WITH PLINABULIN
DECREASED Doses		STABLE Doses
DELAYED Cycles		SUSTAINED Cycles
DOWNGRADE Regimen		STRONGEST Regimen
DISCONTINUED Chemotherapy		STAY the Course

19

1. Data on file. BeyondSpring 2020.

1. B A Y S S D I A
   Q

beyondspringpharma.com

Plinabulin's broad indication presents a market-changing

opportunity

Plinabulin will be indicated for concurrent administration with a myelosuppressive

chemotherapeutic regimen in patients with non-myeloid malignancies for the prevention of CIN

PLINABULIN WILL BE USED WITH:

ALL G-CSFs	ALL CHEMOTHERAPIES	ALL CANCERS

20

PLINABULIN

MARKET RESEARCH FINDINGS

beyondspringpharma.com

1. B

A	Y	Market Research Overview (Summer/Fall '19)
A	S
S
D	I
Q

PROJECT BACKGROUND

• • BUSINESS NEEDS
• BeyondSpring is a US-based, global, clinical-stage biopharmaceutical company developing immuno-oncology therapies
• Plinabulin, currently in phase III clinical trials, will be used in combination with G-CSF therapies for the prevention of CIN

	OBJECTIVES		METHODOLOGY
▪	Assess the potential access and	▪	Phase I - Qualitative Primary Market Research
	reimbursement landscape in the US		(National/Regional Payers, n=10)
▪	Provide purchaser and HCP perspective	▪	Phase II - Qualitative Primary Market Research
	on Plinabulin in the US		(Oncology Practice Managers/Purchasers, n=10)
▪	Understand how Plinabulin will be	▪	Phase III - Quantitative Primary Market Research
	incorporated into clinical practice		(Oncologists, n=110)

22

beyondspringpharma.com

1. B

A	Y	Product differentiation: Target product profile
A	S
S
D	I
Q

Indication:	Plinabulin is indicated for combination use with G-CSF for the prevention of CIN. Plinabulin is a novel, small molecule which acts in a more rapid fashion than standard of care CIN
High Risk CIN	therapies. Additionally, it has demonstrated anti-cancer properties.
Dosing &	Plinabulin: Administered by 30-minute IV infusion on the same day of chemotherapy	Pegfilgrastim (6 mg): Administered 24 hours after chemotherapy infusion either as a SQ
Administration	administration. A single dose starts 30 minutes after chemotherapy infusion per cycle.	injection or an on-body device. A single dose of pegfilgrastim is given per chemotherapy cycle.
Efficacy &		Plinabulin/pegfilgrastim (6 mg) combination is superior in both efficacy and safety to monotherapy pegfilgrastim (6 mg)
Safety
Study Design: Plinabulin/pegfilgrastim combination was evaluated for superiority vs monotherapy pegfilgrastim in patients who were randomized to receive chemotherapy and
	Plinabulin/pegfilgrastim or chemotherapy and pegfilgrastim. Patients were monitored for 4 treatment cycles. All patients were provided best supportive care.
			Plinabulin/pegfilgrastim (6 mg) combination	Pegfilgrastim (6 mg):
		PREVENTION OF GRADE 4 NEUTROPENIA:	40.9%		62.5%
		Duration of Grade 3/4 CIN	0.94 days		1.38 days
	Efficacy
	MEDIAN ANC NADIR	1.00		0.47
	(109 cells/L)	(>50% of patients avoid grade 3 and 4 neutropenia)
		Chemotherapy benefits:	>90%		<85%
		• SUBJECTS MAINTAINING RDI >85%
		6%		12%
		• Subjects with dose delays
		Anti-cancer	Yes (NSCLC study)	No; pegfilgrastim is a growth factor
	Safety	Patients experienced more than 3 days of bone pain	0% (P <.01)		36%
	Neutrophil overshoot	31%		52%

23

beyondspringpharma.com

1. B

A	Y	Oncologist's excitement for Plinabulin
A	S
S
D	I
Q
		Most important factors in choosing to use Plinabulin in
		combination with a G-CSF:

	15%	50%
	Reduction in Relative	Reduction in
	Dose Intensity	Overall Survival
Increase in median Absolute	Ability to maintain
dose/regimen of
Neutrophil Count (ANC) vs.	Reduction in bone pain
chemotherapy
monotherapy G-CSF

Plinabulin's potential direct anti-cancer effect

24

1. B A Y S S D I A
   Q

beyondspringpharma.com

Provider Positive excitement for combination therapy with

Plinabulin

Understanding of combination therapy: high

Likelihood to prescribe: high

RECEPTIVITY TOWARDS	LIKELIHOOD TO USE PLINABULIN + G-CSF
COMBINATION THERAPY	COMBINATION THERAPY
Favor mono	Low
Tx	10%
9%

No

Preference

17%

Moderate

25%

	High
Favor to	65%
Strongly
favor
combination
74%

QB04: On a scale of 1-9, where 1 = Not at all likely to use and 9 = Extremely likely to use, please rate your likelihood to use PLIN + G-CSF combination therapy	25
QB01: How would you characterize the overall clinical benefit of PLIN vs. G-CSFs?

1. B A Y S S D I A
   Q

beyondspringpharma.com

Payer market research: CIN Management

Economic results of CIN are more closely monitored; avoidance of cost - hospitalization - is paramount

Payers leave the decision of treatment modality to the HCP

Clinical Concern

• Infection
• Sepsis
• Febrile Neutropenia

Economic Concern

• ER visits
• Admission into hospital
• Prolonged hospitalization
• Readmission to the hospital

Research indicated that the most compelling attributes of Plinabulin were:

• Reduction in severe neutropenia
• Increase in Median ANC Nadir

26

1. B A Y S S D I A
   Q

beyondspringpharma.com

Provider, patient & payer feedback summary

PATIENTS

• Cancer is the most stress inducing diagnosis
• Patients express a strong desire to follow the treatment plan and realize a good outcome
• Slight changes in the plan can cause great anxiety
• Patients want to stay the course
• Improved outcome and quality of life

PROVIDERS

PAYERS

▪	The majority of HCPs found the
	value proposition of the Plinabulin +
	G-CSF combination compelling and
	are highly likely to prescribe
▪	Superior reduction in Grade 3 and 4
	neutropenia vs. monotherapy G-CSF
▪	Elimination of G-CSF-induced bone
	pain
▪	Increase in Median ANC
▪	Potential reduction of infection and
	death

CLEAR AND

COMPELLING RATIONALE

• The product profile demonstrates significant value for payers to cover Plinabulin as an add-on to G-
  CSF
• Payers consider chemo and G-CSF- related complications to be purview of the HCP
• Reduced clinical concern
• Reduced cost

The potential for improved chemotherapy and improved overall survival
Chemotherapy Without Compromise	27

PLINABULIN

GO-TO-MARKET IMPLICATIONS

beyondspringpharma.com

1. B

A	Y	Chemotherapy Without Compromise
A	S
S
D	I
Q
		Plinabulin's differentiated clinical profile andthe unmet market need enable us to pivot the discussion to
		improving the standard of care in chemotherapy

DECREASED	DELAYED	DOWNGRADE	DISCONTINUED
recommended dose	cycles	chemotherapy regimen	chemotherapy

STABLE	SUSTAINED	STRONGEST	STAY THE
DOSE	CYCLES	REGIMEN	COURSE
maintaining >85%	cycles on time	of chemotherapy	complete all cycles

29

1. B A Y S S D I A
   Q

CLINICAL GAP ANALYSIS

G-CSF monotherapy treatment gap

SCIENTIFIC PLATFORM

• Plinabulin performance
• Value proposition & message development

Congress activities & Peer reviewed publications

MARKET SHAPING

Extensive market research

Message resonance

• Engagement - Targeted customer interactions: KOLs, Payers, Patients
• Speaker mobilization/Education:
  • SOC short fall - 4Ds, 15/50 & OS
• Reimbursement & coding preparation

beyondspringpharma.com

Key commercial actions

LAUNCH STRATEGY

• HCPs - 360⁰ Coverage
• • Comprehensive commercial program
  • Broad HCP & Payer coverage
• Patient support services to ensure ease of use, access and improve care
• Social media across all verticals
• U.S. manufacturing to guarantee supply

KEY MESSAGES:

• Combination therapy superiority
• Improved ANC & Reduced bone pain
• 4Ss - improved chemo flexibility

ACHIEVING IMPROVED CARE

Chemotherapy Without

Compromise

• Greater flexibility in delivering chemotherapy
• Improved clinical outcomes
• Superior market performance

SEASONED COMMERCIAL TEAM

• Complete commercial offering
• Broad coverage of providers, payers and patients across all channels
• Outstanding execution

30

beyondspringpharma.com

1. B

A	Y	Value proposition & Message development
A	S
S
D	I
Q

SCIENTIFIC PLATFORM

• Reduction in:
• • Grade 3 & 4 CIN
  • Bone Pain
• Improvement in:
• • Absolute Neutrophil Count (ANC)
  • Compliance and persistency with chemotherapy
• Potential for:
• • Greater flexibility in chemotherapy care
  • Improved outcomes
  • Prolonged Survival

GLOBAL SCALE

• Multi-nationaloperations
• World-wideclinical programs
• • Chemotherapy induced neutropenia
  • Non small cell lung cancer
• Scalable business model
• Manufacturing:
• • Dynamic
  • Robust
  • Internationally balanced
  • API and Drug Product

PATIENT CENTERED

• Clinical programs designed to provide clinically superior cancer care
• Combination approach is CIN focused on optimizing patient benefit and ease market entry
• Support programs designed to ensure access
• Education programs for Providers, Payers and Patients to drive understanding of differentiation and value
• tailored contracting for launch and long-term access & commercial success

31

beyondspringpharma.com

1. B

A	Y	Launch strategy: Provider, Payer, Patient
A	S
S
D	I
Q

Provider	Payer	Patient
• Promotion	• Access:	The Plinabulin Plus™ Patient Services
	• HCPs - 360⁰ Coverage	• National, Regional & IDNs	Co-Pay Assistance Program
	• High volume G-CSF users	• Targeted contracting
	• Will reduce out-of-pocket costs for
	- Top deciles & KOLs	• Ensure broad availability
	commercially1 insured patients
	- Top clinics/hospitals
	• Awareness, promotion and
		Patient Assistance Program (PAP)
Reimbursement Support	contracting: National Account
Managers	• Plinabulin will be provided at no cost to
•	Coding and billing
	patients facing financial challenges who
•	Dedicated field team
• Education	meet program criteria2
	• Education programs	• Peer-to-peer Programs	Alternative Funding Support
	• On-line/in-person
	- Peer-to-peer;on-line/in-person	Plinabulin Plus™ work with patients to identify
	• CME
	- CME/Promotional	individual programs that provide financial
	• Promotional
	- MSL teams - clinical support	support through independent organization and
	• MSL teams - clinical support	foundations
Peer Reviewed Publications

1	Medicare, Medicaid and Federal/state program patients will not be eligible for the commercial co-pay program	32
2	The Patient Assistance Program will not cover the costs related to Plinabulin infusion

1. B A Y S S D I A
   Q

beyondspringpharma.com

Seasoned commercial team delivering an improved standard

of care; improving chemotherapy

Seasoned leadership team

Experienced in building/scaling organizations and successfully launch products

• Deep oncology experience
• 15+ years of Part B experience
• Multiple specialty and oncology launches

Planning for the Plinabulin launch for over a year

On-going partnership discussions in all major markets

Executed broad-based market research and HCP outreach

Initiated core KOL team identification and buildout

Pre-launch Support

• Key Account managers
• Medical Science Liaisons
• Advisory Boards

Launch Support

• 60 Oncology Account Managers
• 6 Regional Sales Directors
• 6 Key Account Managers
• 6 Field Reimbursement Liaisons
• 7 Medical Scientific Liaisons

33

beyondspringpharma.com

1. B

A	Y	P&L strength enables "go-it-alone" potential in US
A
S	S
D	I
Q		EU is ideal for partnership

US market dynamics

US Strategy		Europe Strategy
Of the that 14 launched in the US…	• Of these launches, we have evidence that 11
subsequently	launched in Europe, choosing to…

and P&L strength		Go-It-Alone		Co-Promote		Go-It-Alone		Out-License
provide	71%				29%		27%		73%
n = 10	n = 4	n = 3	n = 8

BeyondSpring with excellent leverage for partnership

Source: ZS analysis; ZEJULA ex-US rights to Takeda and VARUBI US and Canada rights to TerSera. (3) Post-launch, Ariad sold ex-US rights to Incyte prior to	34
Source: Evaluate Pharma as accessed on February 25th, 2019 and company press releases

beyondspringpharma.com

1. B A Y S S D I A
   Q

Commercial

A growing market

40% increase in	Biosimilars:
chemo cycles by	increase
20401	choice, decrease
	price2

Plinabulin success drivers

Clinical

Improving standard of care

4S	Drive	Anti-	Decrease	Improve
Stable dose,	therapy	cancer	in bone	clinical
Sustained Cycles,	for cure4	benefits5	pain6	flow3
Strongest Regimen,
Stay the Course3

1 Wilson B Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study 2 Coherus/Mylan biosimilars priced at a 33%; Sandoz biosimilar priced at a 37%

discount to Amgen's Neulasta (company press releases); ASP has continued to fall for biosimilars since launch (Redbook, CMS, Bernstein analysis) 3 Lalami Y Impact of CIN and FN on cancer treatment outcome: An overview about well-
established and recently emerging clinical data 4 BYSI primary market research 5 Plinabulin P2 study results 6 Blayney, Douglas, et al, Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN)	35
Prevention, Mobilizes CD34+ Cells through a Mechanism of Action Different from G-CSF and from CXCR4 Inhibition, ASH '18 3 Lalami Y Impact of CIN and FN on cancer treatment outcome: An overview about well-established and recently

emerging clinical data